Industry News

The 4,600-square-meter unit will support development and production of gene and cell therapies, including viral vectors and cell-based products.

The latest installation at the Morpeth, England facility is designed to support rapid changeovers that enhance the site’s oral solid development and production capabilities.

The company has introduced a new cell culture medium designed to optimize high-density gene therapy manufacturing processes.

The new platforms aim to improve speed and scalability in therapeutic protein development, according to the company.

The new medium with integrated insulin aims to increase titers and simplify workflows for biologics manufacturing, according to the company.

Partnerships with the Parker Institute and Children’s Hospital Los Angeles seek to accelerate cancer immunotherapy and pediatric solid tumor research.

The India-headquartered biopharma company has invested more than $30 million in the Cranbury, N.J., site which will produce up to two billion oral solid tablets annually.

The companies said the effort seeks to address current challenges facing CAR-T therapies, including vein-to-vein times of three to five weeks, high costs, and safety risks.

The mammalian and microbial biologic production facility reported a 100% batch success rate and zero findings in ISO certification audits this year.

The Hanover, Maryland company raised funds to scale its nitrogen dioxide sterilization platform as demand grows for alternatives to ethylene oxide.

The 120,000-liter facility known as Plant 1 at the Songdo Bio Campus in Incheon is scheduled for completion in 2026, with commercial operations slated for 2027.

The investment enhances bioavailability capabilities with new closed-loop spray drying technology coupled with existing liquid capsule filling and non-sterile oral liquid formulation...

The multi-year agreement runs through 2029 and marks one of the South Korea-based CDMO’s largest deals to date.

A new 203,000-square-foot site in Vaughan, Ontario expands synthesis capacity to supply complex molecules for drug discovery and global research.

A new “green list” system will allow only approved suppliers of semaglutide and tirzepatide active pharmaceutical ingredients (APIs) into the U.S. market.

The CDMO applied advanced formulation strategies to synchronize the release of active ingredients in NeuroSense’s fixed-dose tablet.

Making CRLs public will help drug developers avoid common missteps, increase insight for healthcare decision making and ensure transparency for investors, said the agency.

The integration expands automation and scalability options for cell therapy process development, according to the companies.

The new facility at its headquarters in Foster City, California will expand biologics capabilities and support technology transfer for next-generation therapies.

With the designation, developers using IRO are expected to gain earlier and more frequent engagement with the agency throughout regulatory processes.

The new facility in Thousand Oaks will unite scientists and engineers to accelerate therapeutic discovery.

The contract with the unidentified company runs through 2030 and supports a Phase 3 program expanding into new indications.

The investment from Quebec government will expand sterile filling capacity and replace most existing equipment at the company’s Boucherville site.

The collaboration links donor material sourcing with GMP manufacturing for autologous and allogeneic therapies.

The Phase II expansion of Production Block 11 at the company’s Bidar, India flagship site makes it the largest reactor block at the location.

The new 75,000-square-foot facility will add large-scale solid- and liquid-phase synthesis capacity to support peptide API demand.

The platform combines physical models and real-time sensory data to improve anomaly detection and predictive maintenance.

The collaboration with the synthetic biology company supports Ottimo’s investigational new drug submission as a potential cancer treatment planned for late 2025.

The Commonwealth experienced a rare decline in jobs in 2024 amid funding constraints and federal uncertainty, according to the 2025 MassBio Industry Snapshot.

The 190,000-square-foot site in West Valley City, Utah is designed to manufacture more than 40 different radioisotopes and up to 12 radioisotopes simultaneously.